Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

被引：0
|
作者：
Yoshinori Munemoto
Mitsuro Kanda
Keiichiro Ishibashi
Taishi Hata
Michiya Kobayashi
Junichi Hasegawa
Mutsumi Fukunaga
Akinori Takagane
Toshio Otsuji
Yasuhiro Miyake
Michitaka Nagase
Junichi Sakamoto
Masaki Matsuoka
Koji Oba
Hideyuki Mishima
机构：
[1] Fukuiken Saiseikai Hospital,Department of Surgery
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)
[3] Saitama Medical Center,Department of Digestive Tract and General Surgery
[4] Saitama Medical University,Department of Gastroenterological Surgery
[5] Osaka University Graduate School of Medicine,Department of Human Health and Medical Sciences
[6] Kochi Medical School,Department of Surgery
[7] Osaka Rosai Hospital,Department of Surgery
[8] Hyogo Prefectural Nishinomiya Hospital,Department of Internal Medicine
[9] Surgical Division,Department of Surgery
[10] Hakodate Goryoukaku Hospital,Department of Surgical Oncology
[11] Dongo Hospital,Department of Biostatistics
[12] Minoh City Hospital Gastrointestinal Research Center,undefined
[13] Gifu University Graduate School of Medicine,undefined
[14] Director,undefined
[15] Tokai Central Hospital,undefined
[16] Matsuoka Clinic,undefined
[17] School of Public Health,undefined
[18] Tokyo University Graduate School of Medicine,undefined
[19] Interfaculty Initiative in Information Studies,undefined
[20] Tokyo University,undefined
[21] Unit of Cancer Center,undefined
[22] Aichi Medical University,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Elderly; Bevacizumab; XELOX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
    Munemoto, Yoshinori
    Kanda, Mitsuro
    Ishibashi, Keiichiro
    Hata, Taishi
    Kobayashi, Michiya
    Hasegawa, Junichi
    Fukunaga, Mutsumi
    Takagane, Akinori
    Otsuji, Toshio
    Miyake, Yasuhiro
    Nagase, Michitaka
    Sakamoto, Junichi
    Matsuoka, Masaki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [2] Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
    Petrioli, Roberto
    Francini, Edoardo
    Cherri, Sara
    Torre, Pamela
    Fiaschi, Anna Ida
    Miano, Salvatora Tindara
    Marrelli, Daniele
    Rovello, Franco
    Francini, Guido
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E663 - E669
  • [3] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, Brigit
    Tamandl, Dietmar
    Schueller, Johannes
    Scheithauer, Werner
    Zielinski, Christoph
    Herbst, Friedrich
    Gruenberger, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835
  • [4] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
  • [5] Clinical Efficacy of Bevacizumab in Conjunction with Oxaliplatin and Capecitabine in Managing Metastatic Colorectal Cancer
    Zang, J.
    Zhang, X.
    Wang, Qing
    Gan, Jianchen
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 290 - 294
  • [6] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
    Hurwitz, H
    Fernando, N
    Yu, DH
    Morse, M
    Blobe, G
    Gockerman, J
    Odogwu, L
    Mahon, M
    Truax, R
    Franklin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 285 - 285
  • [7] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [8] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer.
    Fernando, N
    Yu, D
    Morse, M
    Blobe, G
    Odogwu, L
    Crews, J
    Polito, A
    Honeycutt, W
    Franklin, A
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 260S - 260S
  • [9] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [10] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
12345